Product Portfolio.
Pipeline co-development strategy.
Pipeline Co-Development Strategy
The goal is to increase value along the development chain by way of monetization of select target molecules.
DNX has identified four candidate molecules for half-life extension modification. As illustrated below, DNX's co-development strategy is based on a combination of Internal Product Pipeline Development and Biopharmaceutical Corporate Partnering. The goal is to increase value along the development chain by way of monetization of select target molecules, while focusing attention on taking the lead molecule all the way to the market as DNX's flagship Biobetter product.
In keeping with this philosophy, DNX has either identified and/or chosen its preclinical CRO-, clinical CRO-, CMC- and CMO partners.
This strategy is known to (a) facilitate more rapid product development from discovery stage to complete clinical development in a cost-effective manner and (b) sustain a high level of innovation and generation of new IP.
DNX-114
Treatment of rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
DNX-214
A monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab. An anti-angiogenic that has been approved for the treatment of age-related wet macular degeneration.
DNX-314
Development of the first, half-life extended version of this proven and safe commercially-approved product to target two new indications: osteoarthritis (OA) and type-2 diabetes. A 330-350 fold increase in half-life over the un-modified molecule has been demonstrated in preclinical data.
DNX-414
Treatment of metabolic diseases and diabetes. Preclinical data suggests that the half-life extended molecule has significantly enhanced pharmacological properties over the un-modified molecule in terms circulating half-life, potency levels and solubility.
DNX-514
A FAb fragment of a recombinant human IgG1 monoclonal antibody used as a TNF inhibiting anti-inflammatory drug for the treatment of RA, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.